Pliant Therapeutics, Inc.

NasdaqGS:PLRX Stock Report

Market Cap: US$876.5m

Pliant Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bernard Coulie

Chief executive officer

US$10.9m

Total compensation

CEO salary percentage5.4%
CEO tenure8.1yrs
CEO ownership1.0%
Management average tenure8yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Feb 27
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Jul 21
Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Mar 13
Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Sep 10
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Pliant Therapeutics: Wait For A Better Price To Get In

Aug 20

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Aug 08

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28
Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Pliant's PLN-74809 gets FDA fast track status for liver disease

Jul 21

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Jul 11

Pliant: Major Catalyst Expected Beginning Of 2023

Jun 03

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22
We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29
Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07
We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

May 17
Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 13
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Mar 22
Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Jan 21
We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?

Dec 17
Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?

Pliant Therapeutics (PLRX) Presents At Piper Sandler 32nd Annual Virtual Healthcare Conference - Slideshow

Dec 02

Pliant Therapeutics: An Early Stage Company With Important Collaborations

Nov 23

CEO Compensation Analysis

How has Bernard Coulie's remuneration changed compared to Pliant Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$161m

Sep 30 2023n/an/a

-US$155m

Jun 30 2023n/an/a

-US$144m

Mar 31 2023n/an/a

-US$133m

Dec 31 2022US$11mUS$587k

-US$123m

Sep 30 2022n/an/a

-US$113m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$103m

Dec 31 2021US$5mUS$556k

-US$97m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$2mUS$499k

-US$42m

Sep 30 2020n/an/a

US$18m

Jun 30 2020n/an/a

US$19m

Mar 31 2020n/an/a

US$20m

Dec 31 2019US$2mUS$428k

-US$7m

Compensation vs Market: Bernard's total compensation ($USD10.93M) is above average for companies of similar size in the US market ($USD3.31M).

Compensation vs Earnings: Bernard's compensation has increased whilst the company is unprofitable.


CEO

Bernard Coulie (56 yo)

8.1yrs

Tenure

US$10,927,715

Compensation

Dr. Bernard Coulie, Ph D, M.D. M.B.A. is Director of Septerna, Inc. from February 2024. He serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Independent Chairm...


Leadership Team

NamePositionTenureCompensationOwnership
Bernard Coulie
Presidentno dataUS$10.93m1.04%
$ 9.1m
Keith Cummings
Chief Financial Officer5.3yrsUS$3.44m0.26%
$ 2.3m
Mike Ouimette
General Counsel & Corporate Secretary3.4yrsUS$2.54m0.049%
$ 425.5k
Johannes Hull
Chief Business Officer8yrsUS$3.15m0.30%
$ 2.6m
Éric Lefebvre
Chief Medical Officer5.8yrsUS$3.90mno data
Rik Derynck
Scientific Founder & Member of Scientific Advisory Board9.2yrsno datano data
Dean Sheppard
Scientific Founder & Member of Scientific Advisory Board9.2yrsno datano data
Bill DeGrado
Scientific Founder & Member of Scientific Advisory Board9.2yrsno datano data
Hal Chapman
Scientific Founder & Member of Scientific Advisory Board9.2yrsno datano data
Craig Muir
Interim Chief Technology Officerno datano datano data
Christopher Keenan
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Lily Cheung
Chief Human Resources Officer1.2yrsno data0.0013%
$ 11.6k

8.0yrs

Average Tenure

50yo

Average Age

Experienced Management: PLRX's management team is seasoned and experienced (8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Bernard Coulie
President8.1yrsUS$10.93m1.04%
$ 9.1m
Rik Derynck
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Dean Sheppard
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Bill DeGrado
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Hal Chapman
Scientific Founder & Member of Scientific Advisory Boardno datano datano data
Gayle Crowell
Independent Director4.3yrsUS$116.57k0%
$ 0
Brian Metcalf
Member of Scientific Advisory Boardno datano datano data
Suzanne Bruhn
Independent Director7.7yrsUS$115.07k0.058%
$ 510.5k
John Curnutte
Independent Director6.6yrsUS$114.07k0.049%
$ 426.0k
Hoyoung Huh
Independent Chairman6.3yrsUS$135.07k0.17%
$ 1.5m
Smital Shah
Independent Director5yrsUS$116.07k0%
$ 0
Bill Greenlee
Member of Scientific Advisory Boardno datano datano data

6.4yrs

Average Tenure

60yo

Average Age

Experienced Board: PLRX's board of directors are considered experienced (6.4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.